GO
Loading...

GlaxoSmithKline PLC

More

  • Business Highlights Friday, 19 Sep 2014 | 5:47 PM ET

    NEW YORK— Alibaba debuted as a publicly traded company Friday and swiftly climbed more than 40 percent in a mammoth IPO that offered eager investors seemingly unlimited potential for growth and a way to tap into the burgeoning Chinese middle class.

  • China fines GlaxoSmithKline $492M for bribery Friday, 19 Sep 2014 | 4:22 AM ET

    BEIJING— Drug maker GlaxoSmithKline was fined $492 million on Friday for bribing doctors in China, the biggest such penalty ever imposed by a Chinese court. The court sentenced the company's former China manager, Briton Mark Reilly, and four Chinese co-defendants to prison but postponed the sentences for two to four years, suggesting they may never be served.

  • BEIJING— China fines British drug maker GlaxoSmithKline $492 million, jails executives in bribery case.

  • The candidate Ebola vaccine is being co-developed by the United States National Institutes of Health and the British drugmaker GlaxoSmithKline. The trial will be led by Professor Adrian Hill of the Jenner Institute at Oxford University, which said on Friday the first shot is scheduled to be given to a human volunteer next week.

  • LONDON/ NEW YORK, Sept 12- As electronic cigarettes flew off shelves on both sides of the Atlantic in recent years, investors flocked to a business some hope will be the future for tobacco.

  • The worst-ever Ebola outbreak, which has already killed at least 2,296 people in West Africa, has triggered a scramble to develop the first drug or vaccine for a deadly disease that was discovered nearly 40 years ago in the forests of central Africa.

  • JOHANNESBURG, Sept 10- Aspen Pharmacare is to sell the rights to market a blood clot drug in the United States to rival Mylan Inc for up to $300 million, it said on Wednesday, a move that would help Africa's top generic drugmaker pay down debt.

  • SHANGHAI/ WASHINGTON, Sept 9- A U.S. anti-bribery probe into GlaxoSmithKline Plc touched on the firm's Chinese consumer healthcare business in 2012, internal documents show, suggesting the drugmaker's compliance problems in China could go wider than previously revealed.

  • Sept 4- NewLink Genetics Corp said the U.S. Food and Drug Administration allowed the company to start testing an experimental Ebola vaccine in humans. The move follows a decision to begin initial human testing of a GlaxoSmithKline vaccine this month and an approval to fast track tests of a Johnson& Johnson vaccine.

  • Sept 3- Chimerix Inc said its lead experimental drug showed promise against the deadly Ebola virus in laboratory testing at the U.S. Centers for Disease Control and Prevention and the National Institutes of Health.

  • Sept 2- The U.S. Department of Health and Human Services said on Tuesday a federal contract worth up to $42.3 million would help accelerate testing of an experimental Ebola virus treatment that is being developed by privately held Mapp Biopharmaceutical Inc..

  • PRESS DIGEST-Sunday British Business - AUG 31 Sunday, 31 Aug 2014 | 9:28 AM ET

    LONDON, Aug 31- British newspapers reported the following business stories on Sunday. GlaxoSmithKline is facing a shareholder revolt over plans to shake up its board, with leading investors calling for the speedy departure of Chairman Christopher Gent.

  • The success is therefore a "monumental achievement," virologist Thomas Geisbert of the University of Texas Medical Branch wrote in a commentary on the paper, published online in Nature.

  • Aug 29- BioCryst Pharmaceuticals Inc said it expects to initiate a study within weeks to test its antiviral in primates for use against Ebola infections. This $2.4 million National Institute of Allergy and Infectious Diseases funding is in addition to the $22 million contract awarded to BioCryst by the agency last September.

  • He backed up a short bet; China jailed him for it Friday, 29 Aug 2014 | 12:00 AM ET
    Kun Huang, a Chinese-born Canadian citizen, who is back in Vancouver after spending two years in a Chinese jail, at his lawyer’s office in Vancouver, Canada, Aug. 22, 2014.

    His crime was contributing to research that led his employer to recommend short sales of Silvercorp Metals, a silver producer that is based in Canada but does its mining in China.

  • CHICAGO, Aug 28- Genetic studies of some of the earliest Ebola cases in Sierra Leone reveal more than 300 genetic changes in the virus as it leapt from person to person, changes that could blunt the effectiveness of diagnostic tests and experimental treatments now in development, researchers said on Thursday.

  • GENEVA/ LAGOS Aug 28- The Ebola epidemic in West Africa could infect more than 20,000 people, the U.N. health agency said on Thursday, warning that an international effort costing almost half a billion dollars is needed to overcome the outbreak.

  • Human trials of Ebola vaccine to start next week Thursday, 28 Aug 2014 | 8:09 AM ET
    Medicins Sans Frontieres health workers at an isolation camp in Liberia during the visit of the UN Ebola systems coordinator, Aug. 23, 2014.

    The trials will start at the NIH in Maryland. A vaccine is "the first step in a long process" to control Ebola, Dr. Anthony Fauci says. NBC reports.

  • Early movers: ANF, DG, GS, JPM, C, GSK, WSM & more Thursday, 28 Aug 2014 | 7:58 AM ET

    Some of the names on the move ahead of the open.

  • LONDON/ NEW YORK, Aug 28- An experimental Ebola vaccine from GlaxoSmithKline is being fast-tracked into human studies and the company plans to build a stockpile of up to 10,000 doses for emergency deployment, if results are good.